List of Excipients in Branded Drug TESTIM

Testim Excipient Strategy and Commercial Opportunities in Testosterone Gel

Last updated: September 5, 2026

Testim is a 1% topical testosterone gel whose commercial differentiation depends on skin delivery, dose reproducibility, transfer control, tolerability, packaging and patient adherence. Its labeled excipients are ethanol, purified water, carbomer 980, isopropyl myristate and sodium hydroxide. The principal commercial opportunities are improved dose metering, reduced transfer, lower flammability, better skin tolerability, odor control and differentiated packaging rather than simple substitution of inactive ingredients.

What is the Testim formulation and which excipients does it contain?

Testim is a testosterone gel for topical administration. Each 5-gram tube contains 50 mg of testosterone, with approximately 10% of the applied dose absorbed through the skin under labeled conditions. The product is applied once daily to the shoulders and upper arms. The formulation contains the following inactive ingredients:

Excipient	Functional role in Testim
Ethanol	Solvent, penetration aid, evaporation vehicle and antimicrobial-supporting component
Purified water	Aqueous vehicle
Carbomer 980	Gelling and viscosity-control polymer
Isopropyl myristate	Emollient and skin-penetration enhancer
Sodium hydroxide	pH adjustment and carbomer neutralization

The formulation is an ethanol-water hydroalcoholic gel. Ethanol supports testosterone solubilization and evaporative drying. Isopropyl myristate can improve skin wetting and partitioning of testosterone into the stratum corneum. Carbomer provides the gel structure required for localized application and dosing control. Sodium hydroxide activates the carbomer and adjusts formulation pH.

The FDA-approved product is associated with NDA 021454. FDA approved Testim 1% in 2002 for testosterone replacement therapy in males with conditions associated with a deficiency or absence of endogenous testosterone [1].

How does Testim compare with AndroGel and other testosterone gels?

Testim competes with AndroGel and generic testosterone gels that use the same 1% testosterone strength. The products differ in excipient selection, dose presentation, odor, rheology, application volume and transfer-control instructions.

Product category	Typical strength	Dose presentation	Commercial formulation focus
Testim	1%	Single-use tube, commonly 5 g	Hydroalcoholic gel, skin delivery and tube-based dosing
AndroGel 1%	1%	Packets or pump presentations depending on product	Hydroalcoholic topical delivery and metered dosing
Generic testosterone gel 1%	1%	Tube, packet or pump depending on applicant	Bioequivalence with potential packaging and excipient variation
Testosterone gel 1.62%	1.62%	Metered pump	Lower application volume and dose titration
Testosterone topical solution	Variable	Metered pump or applicator	Fast application and reduced gel residue
Transdermal patch	Variable	Patch	Continuous delivery but higher skin-irritation risk

Testim’s single-use tube format provides a fixed amount of gel, but it creates several commercial disadvantages. Patients must estimate how much of the tube to apply when prescribed a dose below the full tube content. The format also provides less mechanical control over dose delivery than a pump. Residual product in the tube can create handling and disposal issues.

The most direct competitive opportunity is therefore a unit-dose or metered-dose presentation that preserves testosterone exposure while improving application consistency.

What excipient strategy supports a differentiated Testim product?

A successful excipient strategy must preserve testosterone solubility, skin permeation and dose uniformity while improving patient use and safety. The highest-value formulation variables are solvent system, penetration enhancer, polymer architecture, pH, drying time and residue.

Lower-ethanol and solvent-rebalanced systems

Ethanol supports rapid drying and testosterone solubilization, but high alcohol content can cause stinging, dryness and flammability concerns. A reformulated product could reduce ethanol through use of a co-solvent system, a different penetration enhancer or a higher-efficiency solubilization approach.

Potential excipient classes include:

• Propylene glycol or related glycols as co-solvents
• Transcutol-type solvents for skin delivery
• Medium-chain fatty acid esters
• Alternative emollient penetration enhancers
• Volatile and nonvolatile solvent combinations

The commercial value is strongest if the new system reduces irritation without materially slowing drying or increasing transfer to clothing and household contacts.

Improved rheology and application behavior

Carbomer 980 is a conventional and effective gelling polymer, but polymer selection can influence spreadability, tack, drying time and dose uniformity. Opportunities include:

• Lower-tack carbomer systems
• Acrylate crosspolymer systems
• Cellulose-derived polymers
• Rheology modifiers that reduce stringiness
• Polymer blends that improve suspension or solubilization stability

A formulation that spreads over a smaller area and dries more rapidly could support a reduced application burden. The patentability of such a product would depend on demonstrated technical effects, such as improved testosterone flux, reduced residue or reduced interpatient variability.

Skin-tolerability optimization

Topical testosterone products are used chronically. Repeated ethanol exposure, pH effects and penetration enhancers can cause dryness or irritation. Product developers can target:

• Reduced ethanol concentration
• Near-skin-compatible pH
• Lower-irritancy penetration enhancers
• Humectant incorporation
• Less aggressive solvent systems
• Fragrance-free odor-control approaches

The formulation must avoid compromising testosterone absorption. A lower-irritation product with lower systemic exposure would not meet the same therapeutic objective unless the dose and delivery system were redesigned.

What formulations are protected by Testim patents?

Testim’s historical intellectual-property position centered on testosterone gel compositions and topical delivery. U.S. Patent No. 6,503,894 covered testosterone gel formulations associated with the product’s development history. Related continuation and patent-family rights also addressed testosterone gel composition and delivery concepts.

The principal commercial protection for a conventional testosterone gel has weakened because the earliest Testim-related patents were filed more than 20 years ago. The relevant U.S. composition claims have reached or passed their ordinary patent-term endpoint, subject to patent-specific adjustment and jurisdictional status. The commercial barrier has therefore shifted from basic composition ownership to regulatory approval, bioequivalence, manufacturing capability, packaging and lifecycle patents.

A new formulation could still support patent protection if it claims a non-obvious combination of:

• Testosterone concentration and solvent ratio
• Specific penetration-enhancer concentration
• Polymer and neutralization profile
• pH range
• Drying-time performance
• Reduced transfer after a defined drying period
• Improved pharmacokinetic variability
• Lower irritation under repeated-use testing
• Specialized metered-dose packaging

A patent that merely substitutes one commonly used solvent or polymer for another would face a substantial obviousness risk. Stronger claims would connect the excipient combination to measured performance.

When does Testim lose exclusivity and what is the generic entry risk?

Testim’s original FDA approval dates to 2002. Its original statutory exclusivity period has expired. Testosterone gel 1% products have entered the U.S. market through abbreviated new drug applications, creating direct generic competition.

Generic entry risk is high for the conventional 1% gel category because:

1. Testosterone is a well-characterized active ingredient.
2. The dosage form is an established topical gel.
3. The reference formulation and labeling are publicly available.
4. The core product patents are aged.
5. Multiple manufacturers can source standard excipients and packaging.
6. Clinical development requirements are generally lower than for a new molecular entity.

The principal barriers are not discovery-stage science. They are topical bioequivalence, manufacturing consistency, analytical methods, product-performance testing, controlled-substance compliance and commercial scale.

Which companies are challenging or competing with Testim?

Competition comes from generic manufacturers, branded testosterone products and alternative dosage forms rather than from one single challenger.

Relevant competitor groups include:

• Manufacturers of generic testosterone gel 1%
• AbbVie, associated with AndroGel products
• Endo Pharmaceuticals, associated with Testim commercialization
• Manufacturers of testosterone gel 1.62%
• Developers of testosterone topical solutions
• Producers of testosterone patches, injections, buccal systems and oral products

The most important competitive distinction is application format. Pumps and solutions can provide more consistent dosing than a squeeze tube. Injections can offer lower administration frequency but create peak-trough exposure and office or self-injection burdens. Patches avoid some transfer concerns but can produce local skin reactions.

What FDA regulatory pathway applies to an improved Testim formulation?

A generic product that matches the reference product in dosage form, strength, route and critical formulation characteristics generally proceeds through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence and must address topical-product performance.

A materially changed product may require a 505(b)(2) application. This pathway can be relevant when the product changes:

• Excipient composition
• Concentration
• Application site
• Delivery mechanism
• Dose presentation
• Pharmacokinetic profile
• Transfer-control properties

The regulatory strategy depends on whether the change can be bridged to Testim through comparative performance, pharmacokinetic, safety or clinical data. A new pump, lower-alcohol formulation or altered penetration-enhancer system may require more than conventional ANDA evidence if the formulation no longer qualifies as pharmaceutically equivalent to the reference product.

FDA topical-product review focuses on more than plasma testosterone levels. Product developers may need to evaluate dose delivery, content uniformity, adhesion or spreading behavior, skin irritation, sensitization, residual drug, wash-off and transfer to other individuals [2].

What commercial opportunities exist for Testim excipients and packaging?

The strongest opportunities are formulation-plus-device products rather than isolated excipient sales.

Metered-dose pump

A pump can improve dose reproducibility, reduce product waste and support titration. It can also lower direct skin contact with the formulation during dispensing. A pump system may support a differentiated product if it provides validated delivered-dose uniformity across the labeled shelf life.

Low-transfer gel

Testosterone gels carry a boxed warning and prominent labeling concerning secondary exposure to women and children through skin contact. A low-transfer formulation could combine faster drying, reduced residue and a film-forming polymer system.

The regulatory burden is significant because transfer performance must be demonstrated under controlled contact conditions. The commercial benefit is substantial because transfer concerns can limit prescribing and patient acceptance.

Lower-irritation formulation

A formulation with less ethanol or a less aggressive penetration enhancer could improve persistence and adherence among patients who discontinue therapy because of dryness or burning. The product would need to preserve testosterone delivery and avoid longer drying times.

Unit-dose sachets or single-use applicators

Unit-dose packaging can reduce contamination, simplify travel and provide clearer instructions. Its limitations include packaging cost, increased material use and potential difficulty in titrating doses.

Odor and residue control

Odor, stickiness and clothing transfer affect daily use. A fragrance-free system with improved dry-down and reduced tack could offer commercial value without adding a fragrance that introduces sensitization risk.

Excipient and component supplier opportunities

Suppliers can compete through:

• Low-irritation penetration enhancers
• Testosterone-compatible solvent systems
• High-purity carbomer alternatives
• Metered-dose dispensing systems
• Low-permeability laminated tubes
• Airless pump packaging
• Transfer-testing methods
• Stability-indicating analytical methods

The largest defensible opportunity is an integrated formulation and package with performance data, not a commodity excipient alone.

What is the Orange Book status of Testim?

Testim is associated with FDA NDA 021454. The Orange Book remains the authoritative source for current listed patents, exclusivity and reference-product status. Testim’s original exclusivity has expired, and the product has faced generic competition.

For commercial diligence, the key distinction is between historical patents associated with Testim and currently enforceable rights. An expired composition patent does not prevent development of a testosterone gel. A live formulation, device or method-of-use patent could still affect a specific product, but the basic 1% testosterone gel concept is no longer a strong standalone exclusivity platform.

How strong is the Testim patent estate?

The historical Testim estate was meaningful for a conventional ethanol-based testosterone gel during the early commercial period. Its present strength is limited for three reasons:

1. The core filing dates are old.
2. Generic testosterone gels have established market access.
3. Product differentiation now depends on formulation performance and delivery systems.

A new entrant should focus on narrow, technically supported claims covering a specific excipient ratio, delivery device, transfer-reduction result or pharmacokinetic outcome. Broad claims to testosterone in a topical gel are unlikely to provide durable protection against modern competition.

What generic launch scenarios exist for Testim?

Launch scenario	Market effect	Principal risk
Conventional generic 1% gel	Direct price erosion	Rapid substitution and reimbursement pressure
Generic with alternative tube or packet	Moderate differentiation	Limited patient-perceived advantage
Metered pump	Potential premium positioning	Device validation and regulatory burden
Low-transfer formulation	Stronger brand defense	Need for comparative transfer evidence
Low-irritation 505(b)(2) product	Lifecycle opportunity	Additional clinical and regulatory cost
Testosterone solution	Format substitution	Different dosing and labeling requirements

A conventional generic is likely to compete primarily on price. A reformulated product must justify a premium through better adherence, lower transfer risk, easier dosing or improved tolerability.

Key Takeaways

• Testim is a 1% hydroalcoholic testosterone gel containing ethanol, purified water, carbomer 980, isopropyl myristate and sodium hydroxide.
• The most commercially relevant excipient opportunities involve lower irritation, faster drying, reduced transfer and improved dose uniformity.
• The original Testim composition patent position is no longer a strong barrier to conventional generic entry.
• A metered pump, low-transfer gel or lower-ethanol formulation could support meaningful lifecycle differentiation.
• Generic testosterone gel competition is structurally strong because the active ingredient, dosage form and reference-product information are established.
• New intellectual-property value is more likely to arise from specific excipient combinations, measured performance and packaging integration than from broad testosterone-gel claims.
• Testosterone’s controlled-substance status, transfer warnings and chronic-use profile remain central commercial constraints.

FAQs About Testim Excipient Strategy

Can Testim use propylene glycol instead of ethanol?

A reformulated product could use propylene glycol or another co-solvent, but the substitution would require evaluation of testosterone solubility, skin flux, drying time, irritation, stability and bioequivalence. The product may require a 505(b)(2) pathway if the change materially alters the formulation.

Which Testim excipient is most important for skin absorption?

Isopropyl myristate and ethanol are the most commercially relevant penetration-related components. Their effect depends on concentration, vehicle composition, skin condition and the interaction with the carbomer gel matrix.

Can a generic manufacturer copy Testim’s excipients?

A generic manufacturer can generally use the same inactive ingredients if the formulation meets FDA requirements and the product demonstrates pharmaceutical equivalence and bioequivalence. Copying the listed ingredients does not require copying undisclosed manufacturing parameters or exact quantities.

Is a low-transfer testosterone gel patentable?

It can be patentable if the product demonstrates a novel and non-obvious combination that materially reduces transfer while maintaining testosterone delivery. Claims based only on a general statement that the gel dries quickly would be vulnerable without comparative performance data.

Is Testim still commercially attractive?

The conventional product has limited exclusivity-driven attractiveness because generic competition is established. The stronger opportunity is a differentiated successor product with metered dosing, improved tolerability, reduced transfer and a defensible delivery system.

References

1. U.S. Food and Drug Administration. (2002). Testim 1% testosterone gel, NDA 021454: Prescribing information. FDA.
2. U.S. Food and Drug Administration. (2022). Assessment of topical drug products: Guidance for industry. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book]. FDA.
4. DailyMed. (n.d.). Testim testosterone gel, 1%: Label information. National Library of Medicine.
5. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,503,894: Testosterone gel formulation. USPTO.
6. Drug Enforcement Administration. (2023). Controlled substances schedules. U.S. Department of Justice.